Best of ASCO 2009 / GI
|
|
- Berniece Merritt
- 5 years ago
- Views:
Transcription
1 Best of ASCO 2009 / GI Santa Monica, CA J. Randolph Hecht, M.D. Professor of Clinical Medicine Director, UCLA GI Oncology Program David Geffen School of Medicine at UCLA
2 Financial Disclosures I have no relevant financial relationships to disclose Hecht
3 Abstracts Practice Changing:» LBA4509 (ToGA Gastric), 4503 (ABC-2 Biliary), 4505 (ESPAC-3 Pancreas), LBA4007, CRA4008 (STAR, PRODIGE Rectal) Not Practice Changing But Interesting:» LBA4 (C0-8 Colon Adjuvant), 4010 (ACCENT Colon), 4506 (CONKO-4 Pancreas) Life Is Too Short:» 4000 (QUASAR), 4001, 4002 (PETACC-3), 4019 (Leuven) Bonus!:» LBA4009 (ACT-2 Anus), 4508 (PROMID Carcinoid)
4 Practice Changing
5 Gastric Cancer 22,000 cases/yr 12,000 deaths/yr US Jemal, et al., CA Cancer J Clin nd most common cause of cancer and death worldwide Risk has fallen 10 fold over past century
6 Molecular Biology p53: 77% EGFR HER2/neu: Bang ASCO % E-cadherin FHIT p16/p27 COX-2
7 HER-2 in Gastric Cancer HER-2 overexpressed in UGI tumors Amplification correlated with poor outcome N=182 Park DI DDS 2006
8 ToGA!
9 Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer Eric Van Cutsem* Y-K Kang, HC Chung, L Shen, A Sawaki, F Lordick, J Hill, M Lehle, A Feyereislova, Y-J Bang *University Hospital Gasthuisberg, Leuven, Belgium Van Cutsem ASCO 2009
10 ToGA trial design Phase III, randomized, open-label, international, multicenter study 3807 patients screened HER2-positive (22.1%) Stratification factors advanced vs metastatic GC vs GEJ measurable vs non-measurable ECOG PS 0-1 vs 2 capecitabine vs 5-FU HER2-positive advanced GC (n=584) R 5-FU or capecitabine a + cisplatin (n=290) 5-FU or capecitabine a + cisplatin + trastuzumab (n=294) 1 Bang et al; Abstract 4556, ASCO 2009 a Chosen at investigator s discretion GEJ, gastroesophageal junction Van Cutsem ASCO 2009
11 Primary end point: OS Event FC + T FC Events Median OS HR % CI 0.60, 0.91 p value Time (months) No. at risk T, trastuzumab Van Cutsem ASCO 2009
12 Secondary end point: PFS Event FC + T FC Events Median PFS HR % CI 0.59, 0.85 p value Time (months) No. at risk Van Cutsem ASCO 2009
13 Secondary end point: tumor response rate Patients (%) Intent to treat p= F+C + trastuzumab p= F+C 47.3% 41.8% p= % 34.5% 2.4% 5.4% CR PR ORR ORR= CR + PR CR, complete response; PR, partial response Van Cutsem ASCO 2009
14 Conclusions 1. Trastuzumab + chemo is the new SOC for HER-2+ GCs 2. What about esophageal cancer? 3. How do we get trastuzumab? 4. How long? 5. What about lapatanib? LOGIC/ TRIO13: CapeOx +/- lapatanib UGI adenoca 6. Other targets: EGFR, c-met, VEGF
15 ABC
16 Biliary Cancer 9800 cases/year; 3400 deaths/year (Jemal CA 2009) Anecdotal activity with 5-FU, gemcitabine, platins No randomized Ph III trials ABC-1
17
18
19 New Standard of Care
20 Adjuvant Pancreas CONKO-1 Gem > Nothing ESPAC-1 5-FU > Nothing > 5-FU+XRT ESPAC-3 (v2)
21 Neoptolemos ASCO 2009
22
23
24 Conclusions 5-FU = Gem Adjuvant?? XRT All pretty bad
25 Adjuvant Rectal Cancer TME most important Chemoradiation with 5-FU standard of care Preop preferred (dec toxicity, inc sphincter sparing) What does it accomplish? Local control Reduction of distant mets What about other drugs? Irinotecan Oxaliplatin Biological agents
26 Oxaliplatin Improves survival in colon cancer (MOSAIC, C-07) Phase II trials improved pcr rate (5-FU 10-15%, Ox 25-30%) 3 Large Trials STAR ACCORD 12/0405 PRODIGE 2 NSABP R-04 pending
27 STAR STUDY OUTLINE R stage center RT 50.4 Gy FU 225 mg/m 2 /day PVI RT 50.4 Gy FU 225 mg/m 2 /day PVI OXA 60 mg/m 2 weekly x wks T M E FU/LV (bolus or CI, center choice) N = 747 Aschele ASCO 2009
28 Gerard ASCO 2009
29 TUMORS CHARACTERISTICS FU/RT FU/OXA/RT (n=379) (n=368) T stage, % T T T N +, % cm from anal verge median 6 6 TRUS: 33; pelvic CT scan: 261; both 453
30 TOXICITY % of patients FU/RT FU/OXA/RT (n=379) (n=353) p grade III-IV any type 8 24 <.0001 diarrhea 4 15 <.0001 radiation dermatitis grade II-III neurosensory 0.5/0 36/1 <.0001 Tx related deaths 0.3 (1) 0.6 (2)
31 SURGERY patients, % FU/RT (n= 379) FU/OXA/RT (n= 368) Operated LAR APR other 4 5 Median interval 52 days 53 days Deaths < 60 d 0.8 (3) 0.8 (3)
32 pathologic CR patients, % FU/RT FU/OXA/RT (n= 379) (n= 368) p ypt0n (95% cl) (13-20) (13-20)
33 M+ at SURGERY (unplanned / exploratory) patients, n FU/RT FU/OXA/RT (n=379) (n=368) p pm1 11 (3%) 2 (0.5%) liver 6 1 peritoneal 4 1 nodes 1 - cm1 5 - liver 4 - liver+lung 1 - Overall 16 2
34 Oxaliplatin/XRT in Rectal Cancer No improvement in pcr, sphincter sparing Worse toxicity Effect on mets No information on post-op chemo
35 Interesting
36 CRC: Demographics and Presentation Estimated 2008 U.S. incidence (new cases): 148,810 Estimated 2008 U.S. mortality: 49,960 12% stage I * 18.6% stage IV * 24.5% stage II * 12.3% of patients presented with recurrent CRC. *2002 data. 32.6% stage III * American Cancer Society, 2005; Datamonitor, 2003.
37 Adjuvant Therapy of Stage III Disease 5-FU Works!» 5-FU/levamisole NCCTG 31% dec. RFS ECOG 33% improvement OS NCI Consensus 1990» 5-FU/leucovorin NSABP C-04 INT 0089 IMPACT (Pooled)
38 ECOG/INT 0089: Efficacy DFS % of Patients 5-Year 10-Year 5-Year OS 10- Year 5-FU + low-dose LV FU + high-dose LV FU + Lev FU + low-dose LV + Lev P>0.05 in all comparisons except 5-FU + low-dose LV + Lev vs 5-FU + Lev (P<0.05). Haller et al. J Clin Oncol. 2005;23:8671.
39 Combination Chemotherapy 5-FU/Irinotecan» CALBG X C89803» PETACC 3» ACCORD 5-FU/Oxaliplatin» NSABP C-07» MOSAIC
40 MOSAIC: Study Design n=2246 Enrollment: Oct 1998 Jan 2001 (146 centres; 20 countries) Completely resected colon cancer Stage II, 40%; Stage III, 60% Age years KPS 60 No prior chemotherapy R (n=1123) (n=1123) FOLFOX4 (LV5FU2 + oxaliplatin 85 mg/m²) LV5FU2 Primary end-point: disease-free survival Secondary end-points: safety, overall survival LV5FU2, Leucovorin 200 mg/m 2 iv over 2 hours followed by 5-fluorouracil 400 mg/m 2 bolus and 5-fluorouracil 600 mg/m 2 iv over 22 hours on Days 1 and 2, every 14 days; FOLFOX4, LV5FU2 + oxaliplatin 85 mg/m 2 iv over 2 hours on Day 1 De Gramont ASCO 2007
41 Probability MOSAIC Overall Survival: Stage III p= % HR [95% CI] Stage III 0.80 [ ] FOLFOX4 stage III LV5FU2 stage III 0 De Gramont ASCO Overall survival (months)
42 What About Biologic Agents?
43 A phase III trial assessing bevacizumab in stage II and III carcinoma of the colon: Results of NSABP Protocol C-08 N.Wolmark G.Yothers M.J.O Connell S.Sharif N.Atkins T.E.Seay L.Feherenbacher S.O Reilly and C.J.Allegra
44 NSABP C-08 Stage ll + lll Strat: # Pos. N Randomize mff6 mff6 + B
45 NSABP C-08 mff6 q2wk X 6 mo R Bev* q2wk X 1 yr *5mg/K
46 NSABP C-08 DFS % Ev 3yDFS mff6+b mff HR 0.89 P 0.15 Yrs
47 DFS Stage II DFS Stage III Ev 3yDFS mff6+b mff Δ 2.7 Ev 3yDFS mff6+b mff Δ 1.8 HR 0.82 P 0.35 HR 0.90 P 0.25 NSABP C
48 Conclusions There was a transient effect of bevacizumab but NOT clinically significant Awaiting AVANT, what about other trials? (E5202) No evidence for bevacizumab in adjuvant therapy Cetuximab trials pending (PETACC-8; N0147)
49 Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II / III colon cancer: Findings from the ACCENT Database N. Jackson McCleary, J.A. Meyerhardt, E. Green, G. Yothers, A. de Gramont, E. Van Cutsem, M. O Connell, C.J. Twelves, L.B. Saltz, D.J. Sargent for the ACCENT collaborative group
50 Treatment of Colorectal Cancer in Elderly Patients Metastatic setting» Folprecht JCO N=2,692 (22% 70 yrs) 4 trials of irinotecan-based therapy Improved PFS, trend to improved OS for elderly w/addition of irinotecan» Goldberg JCO N=3,742 (16% 70 yrs) 4 trials of oxaliplatin-based therapy Similar survival benefit and toxicity in age subgroups
51 Treatment of Colorectal Cancer in Elderly Patients Adjuvant setting» Sargent NEJM 2001 N=3351 (15% 70 yrs) 7 trials of 5-FU + levamisole/leucovorin v surgery No significant interaction observed between age and efficacy of treatment
52 The Adjuvant Colon Cancer End Points (ACCENT) Group Established in 2003 A collection of individual patient data from trials in the US, Canada, Australia and Europe Original objective - to validate DFS as a surrogate endpoint in adjuvant colon cancer trials O'Connell MJ, et al. JCO 2008; Sargent DJ, et al. JCO 2007; Sargent DJ, et al. JCO 2005
53 Efficacy oxaliplatin-based therapy Age <70 n = 3,977 Endpoint HR (95% CI) Experimental v Control IV 5-FU/LV DFS * OS * TTR * 0.77 (0.68,0.86) 0.81 (0.71,0.93) 0.76 (0.67,0.86) Deaths within 6 mo Exp v Control % (p-value) 0.81 v 0.81 (p=1.0) 70 n = (0.80,1.35) 1.19 (0.90,1.57) 0.92 (0.69,1.23) 2.57 v 1.37 (p=0.25) Interaction of age by treatment p-value * Values < 1 favor experimental arm
54 Conclusions No great rationale for difference with oxaliplatin Why difference between metastatic and adjuvant setting? Hypothesis generating Incorporate in new trials
55 CONKO-4 Trial (4506) Enoxaparin in Advanced Pancreatic Cancer Why?» VTE common in APC»? Therapeutic effect 312 pts svte: 14.5% vs. 5% No change in TTP, OS
56 Conclusions Enoxaparin reduces DVT Is this is worth NNT? No effect on outcome
57 Life Is Too Short Biomarkers Prognostic: How will the patient do? Predictive: Will a specific treatment work? Some markers are both: HER-2 in breast cancer Some markers are only one: KRAS in CRC
58 Life Is Too Short 4000: Oncotype Dx in Stage II CRC Used QUASAR samples and data to validate Recurrence and treatment scores (Prognostic/Predictive) But: Low recurrence score 12% rec rate, high 22% not useful Treatment score not predictive 4001/2: Biomarkers from PETACC-3 Failed adjuvant irinotecan trial MSI progrognostic, Stage II? From III 4019: Retrospective analysis of predictive markers for cetuximab EREG and AREG Already shown (Khambata-Ford JCO 2007)
59 BONUS!!
60 Treatment of Anal Cancer 5-FU/MMC+XRT standard, but high RR with platins in phase II trials RTOG 98-11(Ajani JAMA 2008) Induction chemo, 5-FU/Cis+XRT vs. Standard 5- FU/MMC+XRT
61 RTOG FU/Cis/XRT 5FU/MMC/XRT RFS 54% 60% OS 70% 75% Colostomy rate 19% 10% Ajani 2008
62
63
64
65
66 Anal Cancer 2009 MMC and cisplatin are equivalent Induction therapy is bad What about other agents? Oxaliplatin, cetuximab Hard to do studies
67 Carcinoids Slow growing neuroendocrine tumors Often, though not always hormonally active No standard of care for oncologic treatment Octreotide approved for carcinoid syndrome Rare responses but? increased stable disease
68
69
70
71 Conclusion Octreotide should be the new standard of care for carcinoids What about after progression Other new agents: small molecule VEGFR TKIs, RAD001
72 Best of ASCO 2009 Try to get trastuzumab for HER-2 gastric No oxaliplatin rectal cancer No adjuvant bevacizumab 5-FU OK (barely) pancreatic adjuvant Cisplatin can substitute for MMC in anal cancer Octreotide delays progression in carcinoids
73
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationAdjuvant therapy in older adults: controversies and challenges - Colorectal cancer -
International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie
More informationProgress and Challenges in the Adjuvant Treatment of Stage II & III Colon Cancer
Progress and Challenges in the Adjuvant Treatment of Stage II & III Colon Cancer Professor Eva Segelov Monash Health and Monash University (with thanks to A/P Jeremy Shapiro) Melbourne, Australia Apr 2017
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationWhat Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015
What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 Eileen M. O Reilly, M.D. Associate Director David M. Rubenstein Center Pancreatic Cancer Research
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationTargeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example
Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationIs There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?
Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationUnderstanding predictive and prognostic markers
Understanding predictive and prognostic markers Professor Aimery de Gramont Chairman of ARCAD Foundation and GERCOR, Paris FRANCE Understanding predictive and prognostic markers Aimery de Gramont Prognostic
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationUpper Gastrointestinal Cancers in the Elderly. Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore
Upper Gastrointestinal Cancers in the Elderly Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore Gastric Cancer --High Global Burden Global Cancer Deaths % of all cancer (2008)
More informationAdjuvant treatment for stage II and III Colon Cancer. Ramon Salazar Catalan Institute of Oncology
Adjuvant treatment for stage II and III Colon Cancer Ramon Salazar Catalan Institute of Oncology Disclosures R. Salazar has served in a consultant or advisory role for Amgen, Merck Serono, Taihoo, MSD,
More informationTerapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia
Terapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia Temario Generalidades Adyuvancia en colon y recto FU / Capecitabina
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationCOLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More information(Neo-) adjuvant Treatment of Gastric Cancer. - The European View
(Neo-) adjuvant Treatment of Gastric Cancer - The European View Florian Lordick, MD Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) University of Leipzig, Germany My Conflict
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationColorectal Cancer Update Dr. Barb Melosky
Colorectal Cancer Update 2017 Dr. Barb Melosky bmelosky@bccancer.bc.ca Disclosure Research Support/P.I. Honoraria/Advisory Board Bayer Roche, Amgen, Bayer, Lilly Objectives 1) Demonstrate knowledge of
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationColon, Rectum, and Appendix
Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline
More informationColon, Rectum, and Appendix. Presentation Outline. Overview Tumor Characteristics
Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Rectal Cancer Pathway V8, April 2015 Diagnostic Workup: Bethesda Criteria: Pathology Review All patients H&P All patients Biopsy All patients Colonoscopy All patients CEA All Patients Chest/Abdominal/Pelvic
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More informationWhere are we in 2013?
The Use of Gene Profile Testing in the Adjuvant Therapy of Stages II & III Colon Cancer: Where are we in 2013? Howard S. Hochster, MD Professor of Medicine, Yale School of Medicine Associate Director,
More informationTreatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations
Treatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations D Papamichael MB BS FRCP On behalf of the SIOG CRC in the Elderly Task Force Madrid 10/11/07 8 th Meeting of the International
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationManagement of early rectal cancer: Any role for adjuvant chemotherapy
Management of early rectal cancer: Any role for adjuvant chemotherapy Andrés Cervantes Professor of Medicine CURRENTS CONCEPTS IN RECTAL CANCER DIAGNOSIS AND THERAPY TME surgery Optimal staging by MRI
More informationGastrointestinal Cancers:
Year in Review Gastrointestinal Cancers: 2009-2010 2010 Vol 1 Issue 1 A CME monograph and speaker s slide kit summarizing the year s most important meeting presentations and journal articles Gastrointestinal
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationPancreatic Ca Update
Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationTHE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER
THE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Dept of GI Medical Oncology November 5, 2010
More informationChemotherapy options and outcomes in older adult patients with colorectal cancer
Critical Reviews in Oncology/Hematology 72 (2009) 155 169 Chemotherapy options and outcomes in older adult patients with colorectal cancer Muhammad W. Saif a,, Stuart M. Lichtman b a Yale University School
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationLindsay A. Renfro, Daniel J. Sargent. Statistics in Oncology Clinical Trials
Page 1 of 11 Editor s note: The special column Statistics in Oncology Clinical Trials is dedicated to providing state-of-the-art review or perspectives of statistical issues in oncology clinical trials.
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationDr Roopinder Gillmore July 2017
Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not
More informationSIOG CRC Guidelines D Papamichael MB BS FRCP Cyprus Oncology Centre SIOG 2014 Special SIOG Guidelines Session
SIOG CRC Guidelines D Papamichael MB BS FRCP Cyprus Oncology Centre SIOG 2014 Special SIOG Guidelines Session Lisbon October 25 th Outline Background Surgery in older adults Adjuvant therapy - Single agent
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationSystemic Cytotoxic Therapy in advanced HCC
Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationtrial update clinical
clinical trial update by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UMPC Cancer Centers In order to provide the most up-to-date and efficacious care to their patients, oncologists must
More information2/20/14& Medical Management of Colon and Rectal Cancer: An Overview. Outline / Learning Objectives. How common is colon cancer?
Medical Management of Colon and Rectal Cancer: An Overview Jonathan Grim, MD, PhD VA Puget Sound Health Care System Fred Hutchinson Cancer Research Center UW Medicine Outline / Learning Objectives Epidemiology
More informationUpdated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)
Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More information